Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBT Margin (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed EBT Margin for 4 consecutive years, with 463.85% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 43892.0% to 463.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1036.91% through Dec 2025, down 2142.0% year-over-year, with the annual reading at 1036.91% for FY2025, 2142.0% down from the prior year.
  • EBT Margin hit 463.85% in Q4 2025 for Taysha Gene Therapies, up from 1254.33% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 620562.5% in Q1 2022 to a low of 1788.31% in Q2 2024.
  • Historically, EBT Margin has averaged 41492.2% across 4 years, with a median of 463.85% in 2025.
  • Biggest five-year swings in EBT Margin: tumbled -62093679bps in 2023 and later surged 53398bps in 2025.
  • Year by year, EBT Margin stood at 4220.08% in 2022, then plummeted by -110bps to 417.26% in 2023, then plummeted by -116bps to 902.77% in 2024, then surged by 49bps to 463.85% in 2025.
  • Business Quant data shows EBT Margin for TSHA at 463.85% in Q4 2025, 1254.33% in Q2 2025, and 873.76% in Q1 2025.